trending Market Intelligence /marketintelligence/en/news-insights/trending/v_KrETzkJ03GcKLlPke6gg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

Sinopharm Group FY'18 profit up 4.7% YOY

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Sinopharm Group FY'18 profit up 4.7% YOY

Shanghai-based Sinopharm Group Co. Ltd.'s profit for full year 2018 grew 4.7% year over year.

Profit attributable to equity holders of the parent reached 5.84 billion yuan, from 5.58 billion yuan in 2017.

Diluted EPS was 1.97 yuan, compared to 1.88 yuan a year earlier.

Revenue for the year ended Dec. 31, 2018, grew 11.7% to 344.53 billion yuan, from 308.35 billion in 2017.

Revenue from the company's pharmaceutical distribution segment, which represents 80.4% of the group's total revenue, grew 9.3% to 281.05 billion.

Sinopharm, a wholesaler and retailer of pharmaceutical and healthcare products, booked 2018 operating profit of 15.40 billion yuan, from 13.14 billion a year earlier.

As of March 22, US$1 was equivalent to 6.72 Chinese yuan.